JP2013512899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512899A5 JP2013512899A5 JP2012541997A JP2012541997A JP2013512899A5 JP 2013512899 A5 JP2013512899 A5 JP 2013512899A5 JP 2012541997 A JP2012541997 A JP 2012541997A JP 2012541997 A JP2012541997 A JP 2012541997A JP 2013512899 A5 JP2013512899 A5 JP 2013512899A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- piperazin
- chlorophenyl
- oxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-{[2- (4-chlorophenyl) -4,4 -Dimethylcyclohex-1-en-1-yl] methyl} piperazin-1-yl Chemical group 0.000 claims 92
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 65
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000000277 Splenic Neoplasms Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000006491 bone marrow cancer Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000025113 myeloid leukemia Diseases 0.000 claims 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 201000002471 spleen cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- XDOCKJXYYKYDQV-UHFFFAOYSA-N n-[4-[[2-(6-amino-5-chloropyridin-3-yl)oxy-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-nitrophenyl]morpholine-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C(Cl)C(N)=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(=O)N1CCOCC1 XDOCKJXYYKYDQV-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/631,367 | 2009-12-04 | ||
| US12/631,367 US20100160322A1 (en) | 2008-12-04 | 2009-12-04 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PCT/US2010/036844 WO2011068560A1 (en) | 2009-12-04 | 2010-06-01 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512899A JP2013512899A (ja) | 2013-04-18 |
| JP2013512899A5 true JP2013512899A5 (https=) | 2013-07-11 |
| JP5589090B2 JP5589090B2 (ja) | 2014-09-10 |
Family
ID=42463423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541997A Active JP5589090B2 (ja) | 2009-12-04 | 2010-06-01 | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20100160322A1 (https=) |
| EP (1) | EP2507211B1 (https=) |
| JP (1) | JP5589090B2 (https=) |
| CN (2) | CN103097352A (https=) |
| AR (1) | AR076946A1 (https=) |
| AU (1) | AU2010326727B2 (https=) |
| BR (1) | BR112012012918A8 (https=) |
| CA (1) | CA2781521A1 (https=) |
| CL (1) | CL2012001421A1 (https=) |
| CO (1) | CO6571908A2 (https=) |
| CR (1) | CR20120347A (https=) |
| CY (1) | CY1115502T1 (https=) |
| DK (1) | DK2507211T3 (https=) |
| DO (1) | DOP2012000154A (https=) |
| EC (1) | ECSP12012020A (https=) |
| ES (1) | ES2487617T3 (https=) |
| IL (1) | IL219991A (https=) |
| MX (1) | MX2012006391A (https=) |
| MY (1) | MY161340A (https=) |
| NZ (1) | NZ600084A (https=) |
| PE (1) | PE20121496A1 (https=) |
| PH (1) | PH12012501071A1 (https=) |
| PL (1) | PL2507211T3 (https=) |
| PT (1) | PT2507211E (https=) |
| RU (1) | RU2535203C2 (https=) |
| SG (1) | SG181506A1 (https=) |
| SI (1) | SI2507211T1 (https=) |
| TW (1) | TWI473801B (https=) |
| UA (1) | UA106403C2 (https=) |
| WO (1) | WO2011068560A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CN102282128B (zh) * | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| CN102282129A (zh) * | 2009-01-19 | 2011-12-14 | 雅培制药有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ595708A (en) * | 2009-05-26 | 2014-03-28 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2011119345A2 (en) * | 2010-03-25 | 2011-09-29 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| CA3152557A1 (en) * | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| TWI620736B (zh) | 2010-11-23 | 2018-04-11 | 艾伯維巴哈馬有限公司 | 使用選擇性bcl-2抑制劑之治療方法 |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2013059738A2 (en) * | 2011-10-19 | 2013-04-25 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| UY39848A (es) * | 2013-03-13 | 2022-09-30 | Abbvie Ireland Unlimited Co | Procesos para la preparación de un agente inductor de la apoptosis |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| MA40596B1 (fr) | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| MA41051B1 (fr) | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| CA3019380A1 (en) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN110759908B (zh) * | 2017-06-26 | 2021-03-12 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| JP7121794B2 (ja) | 2017-08-02 | 2022-08-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピロリジン化合物を調製するためのプロセス |
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| EP3720849A2 (en) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| EP3737681A4 (en) | 2018-01-10 | 2022-01-12 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CN109851535A (zh) * | 2019-01-30 | 2019-06-07 | 天津现代职业技术学院 | 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法 |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN113444078B (zh) * | 2020-03-25 | 2023-07-07 | 中国科学院上海有机化学研究所 | 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用 |
| CN111978246A (zh) * | 2020-09-26 | 2020-11-24 | 安徽金禾实业股份有限公司 | 一种2-甲基-3-甲氧基-4-氯吡啶的纯化合成方法 |
| CN117616023A (zh) * | 2021-04-13 | 2024-02-27 | 爱新医药科技(香港)有限公司 | Bcl-2或bcl-2/bcl-xl调节剂及其用途 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4126937A1 (de) | 1991-08-10 | 1993-02-11 | Basf Ag | Salicyl(thio)etherderivate, verfahren und zwischenprodukte zu ihrer herstellung |
| CA2115990A1 (en) | 1991-08-19 | 1993-03-04 | George Albert Boswell | Angiotensin ii receptor blocking imidazolinone derivatives |
| GB9203798D0 (en) | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
| WO1999006433A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| RU2208609C2 (ru) | 1998-02-04 | 2003-07-20 | Новартис Аг | Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| DE19830430A1 (de) * | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| WO2000037436A1 (en) * | 1998-12-22 | 2000-06-29 | F. Hoffmann-La Roche Ag | Sulfonamide hydroxamates |
| GB9918037D0 (en) * | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| KR20020060160A (ko) | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
| EP1265864A1 (en) | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| IL151250A0 (en) | 2000-03-21 | 2003-04-10 | Procter & Gamble | Difluorobutyric acid metalloprotease inhibitors |
| US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| CZ20033296A3 (cs) | 2001-06-06 | 2004-04-14 | Eli Lilly And Company | Benzoylsulfonamidy a sulfonylbenzamidiny jako protinádorové sloučeniny |
| GT200200188A (es) | 2001-09-24 | 2003-06-25 | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad | |
| AR043059A1 (es) | 2002-11-12 | 2005-07-13 | Bayer Pharmaceuticals Corp | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos |
| DE60316984T2 (de) | 2002-11-22 | 2008-07-17 | Eli Lilly And Co., Indianapolis | Benzoylsulfonamide als antitumor-mittel |
| WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) * | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| JP2007512526A (ja) * | 2003-11-20 | 2007-05-17 | フレッシュポイント・ホールディングス・ソシエテ・アノニム | 時間温度指標の状態を測定する方法及びシステム |
| RU2263666C1 (ru) | 2004-04-08 | 2005-11-10 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Гетероциклилсульфиновые кислоты и их производные, фокусированная библиотека и фармацевтическая композиция |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| ATE548359T1 (de) | 2004-06-17 | 2012-03-15 | Infinity Discovery Inc | Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern |
| EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
| WO2006039164A2 (en) * | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| EP1888550B1 (en) * | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) * | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| US20100087436A1 (en) | 2006-11-16 | 2010-04-08 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| CA2676944C (en) | 2007-02-15 | 2016-01-19 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| JP2010524972A (ja) * | 2007-04-19 | 2010-07-22 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化したモルホリニル化合物 |
| US7531685B2 (en) * | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| EP2231159A1 (en) | 2007-11-16 | 2010-09-29 | Abbott Laboratories | Method of treating arthritis |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| HUE029289T2 (en) * | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases |
| CN102282128B (zh) | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| CN102282129A (zh) | 2009-01-19 | 2011-12-14 | 雅培制药有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ595708A (en) * | 2009-05-26 | 2014-03-28 | Abbvie Bahamas Ltd | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2009
- 2009-12-04 US US12/631,367 patent/US20100160322A1/en not_active Abandoned
-
2010
- 2010-06-01 DK DK10722500.5T patent/DK2507211T3/da active
- 2010-06-01 UA UAA201208181A patent/UA106403C2/ru unknown
- 2010-06-01 PT PT107225005T patent/PT2507211E/pt unknown
- 2010-06-01 CN CN201080065339XA patent/CN103097352A/zh active Pending
- 2010-06-01 BR BR112012012918A patent/BR112012012918A8/pt not_active Application Discontinuation
- 2010-06-01 WO PCT/US2010/036844 patent/WO2011068560A1/en not_active Ceased
- 2010-06-01 PE PE2012000765A patent/PE20121496A1/es active IP Right Grant
- 2010-06-01 RU RU2012127790/04A patent/RU2535203C2/ru active
- 2010-06-01 MY MYPI2012700318A patent/MY161340A/en unknown
- 2010-06-01 EP EP10722500.5A patent/EP2507211B1/en active Active
- 2010-06-01 SI SI201030743T patent/SI2507211T1/sl unknown
- 2010-06-01 JP JP2012541997A patent/JP5589090B2/ja active Active
- 2010-06-01 ES ES10722500.5T patent/ES2487617T3/es active Active
- 2010-06-01 CN CN201610801580.3A patent/CN106397418A/zh active Pending
- 2010-06-01 CA CA2781521A patent/CA2781521A1/en not_active Abandoned
- 2010-06-01 PL PL10722500T patent/PL2507211T3/pl unknown
- 2010-06-01 MX MX2012006391A patent/MX2012006391A/es unknown
- 2010-06-01 AU AU2010326727A patent/AU2010326727B2/en not_active Ceased
- 2010-06-01 SG SG2012041018A patent/SG181506A1/en unknown
- 2010-06-01 PH PH1/2012/501071A patent/PH12012501071A1/en unknown
- 2010-06-01 NZ NZ600084A patent/NZ600084A/en not_active IP Right Cessation
- 2010-06-02 TW TW99117829A patent/TWI473801B/zh not_active IP Right Cessation
- 2010-06-02 AR ARP100101936A patent/AR076946A1/es unknown
-
2012
- 2012-05-24 IL IL219991A patent/IL219991A/en active IP Right Grant
- 2012-05-31 CL CL2012001421A patent/CL2012001421A1/es unknown
- 2012-06-01 DO DO2012000154A patent/DOP2012000154A/es unknown
- 2012-06-07 CO CO12096369A patent/CO6571908A2/es active IP Right Grant
- 2012-06-25 CR CR20120347A patent/CR20120347A/es unknown
- 2012-07-03 EC ECSP12012020 patent/ECSP12012020A/es unknown
-
2013
- 2013-07-26 US US13/952,278 patent/US8952157B2/en active Active
-
2014
- 2014-08-27 CY CY20141100684T patent/CY1115502T1/el unknown
- 2014-12-23 US US14/582,144 patent/US9303025B2/en active Active
-
2016
- 2016-02-19 US US15/048,901 patent/US20160304451A1/en not_active Abandoned
-
2017
- 2017-10-13 US US15/783,993 patent/US20180251426A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512899A5 (https=) | ||
| RU2012127790A (ru) | Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний | |
| RU2497822C2 (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2013512900A5 (https=) | ||
| RU2012127760A (ru) | Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний | |
| JP2013527202A5 (https=) | ||
| JP2016517406A5 (https=) | ||
| JP2019038820A5 (https=) | ||
| JP2018138577A5 (https=) | ||
| RU2015141713A (ru) | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний | |
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| NZ593593A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| RU2458920C2 (ru) | Новые соединения | |
| JP2011524906A5 (https=) | ||
| JP2022043059A5 (https=) | ||
| JP2013523636A5 (https=) | ||
| JP2021512143A5 (https=) | ||
| JP2012530705A5 (https=) | ||
| JP2007519754A5 (https=) | ||
| HRP20150925T1 (hr) | Agensi koji induciraju apoptozu za lijeäśenje raka te imunih i autoimunih bolesti | |
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2010538076A5 (https=) | ||
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| JP2013517283A5 (https=) | ||
| NZ593594A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |